Akeso

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: $5B

Website

Clinical Trials

A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Healthy Male Chinese Subjects

Not Applicable

Not yet recruiting

Conditions: Healthy Subjects

Interventions: Drug: Ebronucimab

First Posted Date: 2025-06-29

Last Posted Date: 2025-06-29

Lead Sponsor: Akeso

Target Recruit Count: 204

Registration Number: NCT07043283

A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

Phase 3

Not yet recruiting

Conditions: Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions: Drug: Cadonilimab
Drug: SOX chemotherapy

First Posted Date: 2025-06-16

Last Posted Date: 2025-06-16

Lead Sponsor: Akeso

Target Recruit Count: 760

Registration Number: NCT07023315

Locations: 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
🇨🇳
Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
🇨🇳
Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

and more 3 locations

A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Phase 3

Not yet recruiting

Conditions: Small Cell Lung Cancer

Interventions: Drug: AK112
Other: Placebo

First Posted Date: 2025-06-08

Last Posted Date: 2025-06-08

Lead Sponsor: Akeso

Target Recruit Count: 480

Registration Number: NCT07010263

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
The First Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China
🇨🇳
Beijing Chest Hospital, Beijing, Beijing, China

and more 37 locations

A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

Phase 2

Not yet recruiting

Conditions: HCC
Hepatocellular Carcinoma

Interventions: Biological: AK104+lenvatinib
Drug: lenvatinib

First Posted Date: 2025-05-22

Last Posted Date: 2025-05-22

Lead Sponsor: Akeso

Target Recruit Count: 120

Registration Number: NCT06984718

A Phase III Study of Ivonescimab + Chemo With/Without AK117 vs Chemo in Metastatic Pancreatic Cancer

Phase 3

Not yet recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine
Drug: Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine
Drug: Ivonescimab Placebo, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine

First Posted Date: 2025-05-01

Last Posted Date: 2025-05-01

Lead Sponsor: Akeso

Target Recruit Count: 999

Registration Number: NCT06953999

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

A Phase III, Randomized, Controlled and Multi-center Study of AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

Phase 3

Not yet recruiting

Conditions: Colorectal Adenocarcinoma

Interventions: Drug: AK112
Drug: Oxaliplatin
Drug: Irinotecan
Drug: Leucovorin and 5-FU
Drug: Bevacizumab

First Posted Date: 2025-04-30

Last Posted Date: 2025-04-30

Lead Sponsor: Akeso

Target Recruit Count: 560

Registration Number: NCT06951503

Locations: 🇨🇳
The Sixth Hospital,Sun Yat-sen University, Guanzhou, Guangdong, China
🇨🇳
Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China

A Clinical Study of AK139 in Healthy Subjects

Phase 1

Not yet recruiting

Conditions: Healthy Subjects

Interventions: Drug: AK111
Drug: Placebo

First Posted Date: 2025-04-27

Last Posted Date: 2025-04-27

Lead Sponsor: Akeso

Target Recruit Count: 48

Registration Number: NCT06947109

AK129 Combination Therapy for Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Non-small Cell Lung Cancer Stage IIIB/IV
Head and Neck Squamous Cell Carcinoma (HNSCC)
Colorectal Adenocarcinoma
Advanced Solid Tumors

Interventions: Drug: Pemetrexed
Drug: Cetuximab
Drug: Chemotherapy
Drug: AK129(dose 1)
Drug: Cis-platinum
Drug: Carboplatin
Drug: Paclitaxel
Drug: 5-FU (5-fluorouracil)
Drug: Docetaxel
Drug: AK129(dose 2)
Drug: AK129(RP2D)
Drug: Penpulimab

First Posted Date: 2025-04-24

Last Posted Date: 2025-06-03

Lead Sponsor: Akeso

Target Recruit Count: 230

Registration Number: NCT06943820

Locations: 🇨🇳
Liaoning Cancer Hospital, Shenyang, Liaoning, China

A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer

Phase 1

Not yet recruiting

Conditions: Biliary Tract Cancer

Interventions: Drug: AK112
Drug: AK130

First Posted Date: 2025-04-22

Last Posted Date: 2025-04-22

Lead Sponsor: Akeso

Target Recruit Count: 135

Registration Number: NCT06938321

Locations: 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: AK146D1 for injection

First Posted Date: 2025-04-16

Last Posted Date: 2025-04-16

Lead Sponsor: Akeso

Target Recruit Count: 48

Registration Number: NCT06929663

AI-Powered Research

Premium Access

Akeso

A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Healthy Male Chinese Subjects

A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

A Phase III Study of Ivonescimab + Chemo With/Without AK117 vs Chemo in Metastatic Pancreatic Cancer

A Phase III, Randomized, Controlled and Multi-center Study of AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

A Clinical Study of AK139 in Healthy Subjects

AK129 Combination Therapy for Advanced Solid Tumors

A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer

A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors